Evidence map›Paper›PMID 42487093›Full record

ArticleDrug delivery and translational research2026

Fucoidan-based microneedle patch for delivery of IGF1-loaded exosomes in diabetic wound therapy.

Marjan Mirhaj, Jaleh Varshosaz, Nada A Kadhim, Marwa M Kamil, Maha Hameed Al-Bahrani, Mastafa H Al-Musawi, Sheida Mani, Fariborz Sharifianjazi, Ketevan Tavamaishvili, Mohamadreza Tavakoli and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marjan MirhajDepartment of Materials Engineering, Isfahan University of Technology, Isfahan, 84156-83111, Iran.
Jaleh VarshosazNovel Drug Delivery Systems Research Centre, Department of Pharmaceutics, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. varshosaz@pharm.mui.ac.ir.ORCID https://orcid.org/0000-0001-9333-5798
Nada A KadhimDepartment of Chemistry, College of Science, University of Baghdad, Baghdad, Iraq.
Marwa M KamilDepartment of Pharmaceutics, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq.
Maha Hameed Al-BahraniDepartment of Molecular and Medical Biotechnology, College of Biotechnology, Al-Nahrain University, Baghdad, Iraq.
Mastafa H Al-MusawiDepartment of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq.
Sheida ManiPharmacy graduate Research Committee, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Fariborz SharifianjaziCenter for Advanced Materials and Structures, School of Science and Technology, The University of Georgia, Tbilisi, 0171, Georgia.
Ketevan TavamaishviliSchool of Medicine, Georgian American University, 10 Merab Aleksidze Str, Tbilisi, 0160, Georgia.
Mohamadreza TavakoliDepartment of Materials Engineering, Isfahan University of Technology, Isfahan, 84156-83111, Iran.
Mina Shahriari KhalajiDepartment of Biomedical Engineering, Rowan University, Glassboro, NJ, 08028, USA.

Funding

Isfahan University of Medical Sciences 1402350
6 · The paper itself

Abstract

Diabetic wounds often lead to significant therapeutic challenges due to impaired vascularization, chronic inflammation, and poor drug penetration. This study presents a polyallylamine hydrochloride-fucoidan (PAH.Fc) hydrogel-based microneedle patch for site specific delivery of IGF1-incorporated exosomal vesicles obtained from adipose-derived stem cells (ADSC-Exos) to diabetic wounds. The average size of IGF1-loaded ADSC-Exos was measured as 261.81 nm. The fabricated microneedles exhibited swelling ratios between 228.0% and 247.1%, with a degradation rate of 47.56% after 7 days of immersion in PBS. IGF1 release was sustained and time-dependent, reaching 89.25 ± 4.60% over 168 h. MTT assay confirmed cytocompatibility, with HaCaT cell viability exceeding 80% across all groups. Nile Red labeling demonstrated efficient cellular uptake of both ADSC-Exos and IGF1-loaded ADSC-Exos by HaCaT cells, and CAM assay results revealed that the PAH.Fc/IGF1 Exos induced the highest angiogenic response among tested groups. In vivo studies using a hyperglycemic rat model showed near-complete wound closure within 14 days in the PAH.Fc/IGF1 Exo-treated group, accompanied by elevated expression of VEGF and TGF-β and reduced levels of pro-inflammatory markers TNF-α and IL-1β. Collectively, these findings demonstrate that the PAH.Fc/IGF1 Exo microneedle patch offers optimized local delivery of bioactive cargo and holds strong therapeutic potential for chronic wound management, particularly in diabetic wound healing.

Indexed as

Diabetic wound healingExosomeFucoidanInsulin-like growth factorMicroneedle patch

Identifiers

PMID42487093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.